DenovoSkin is named as an intervention in 2 current clinical trials in our Italy, Netherlands, Switzerland, Germany, France, Spain, Belgium, Poland and Portugal registers. 1 is recruiting patients now. The most common phase is Phase 3. The lead sponsor is CUTISS AG. The most-studied condition is Burns.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
NCT06745557 · ClinicalTrials.gov ↗ · Burns
|
Phase 3 | Recruiting | CUTISS AG | Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Portugal |
|
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children
NCT03229564 · ClinicalTrials.gov ↗ · Burns
|
Phase 2 | Active, closed | CUTISS AG | Italy, Netherlands, Switzerland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| CUTISS AG | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Italy, Netherlands, Switzerland, Germany, France, Spain, Belgium, Poland and Portugal registers name DenovoSkin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Switzerland, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Belgium, 1 with sites in Poland and 1 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is CUTISS AG. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how DenovoSkin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how DenovoSkin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists DenovoSkin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.